<DOC>
	<DOC>NCT02771340</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.</brief_summary>
	<brief_title>Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Choroid Neoplasms</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Males or females of any race at least 18 years of age Clinical diagnosis of primary uveal melanoma involving the posterior uveal tract in the study eye Planned enucleation or brachytherapy of the study eye due to uveal melanoma Uveal melanoma in the study eye originating in the anterior uveal tract (iris) Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia) Woman who is pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>